What question did this study set out to answer?

The study aims to compare the effectiveness of sequential nephron blockade versus sequential renin–angiotensin system blockade on blood pressure.

April 10, 2026

Sequential nephron blockade vs . sequential renin–angiotensin system blockade on central and ambulatory blood pressure in resistant hypertension: A randomized clinical trial

Key Result

Sequential nephron blockade better reduced central systolic and pulse pressure, while renin-angiotensin system blockade more effectively lowered heart rate in resistant hypertension.

Key Points

The study aims to compare the effectiveness of sequential nephron blockade versus sequential renin–angiotensin system blockade on blood pressure.
Randomized clinical trial design
Patient population with resistant hypertension
Comparison of sequential nephron blockade and renin–angiotensin system blockade
Measurement of central and ambulatory blood pressure outcomes
Sequential nephron blockade showed greater reduction in central systolic blood pressure and pulse pressure
Renin–angiotensin system blockade was more effective at lowering heart rate
Distinct hemodynamic responses suggest different treatment strategies for patients

Structured PICO

Does sequential nephron blockade improve central and ambulatory blood pressure compared to sequential renin-angiotensin system blockade in patients with resistant hypertension?

P

Population

Patients with resistant hypertension (RHTN)

I

Intervention

Sequential nephron blockade (SNB)

C

Comparator

Sequential renin-angiotensin system blockade (RASSB)

O

Outcome

Central and ambulatory blood pressuresurrogate

Sequential nephron blockade and sequential renin-angiotensin system blockade have distinct hemodynamic effects in resistant hypertension, supporting individualized treatment strategies.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

SNB demonstrated superior efficacy in reducing CSBP and pulse pressure, while RASSB more effectively lowered heart rate. These distinct haemodynamic responses support individualized treatment strategies for patients with RHTN.